Cargando…

Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway

BACKGROUND: Cardiotoxic side effects impose limits to the use of anti-tumour chemotherapeutic drugs such as doxorubicin (Dox). There is a need for cardioprotective strategies to prevent the multiple deleterious effects of Dox. Here, we examined the ability of administered fibroblast growth factor-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Koleini, Navid, Nickel, Barbara E., Wang, Jie, Roveimiab, Zeinab, Fandrich, Robert R., Kirshenbaum, Lorrie A., Cattini, Peter A., Kardami, Elissavet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675643/
https://www.ncbi.nlm.nih.gov/pubmed/29152091
http://dx.doi.org/10.18632/oncotarget.20558
_version_ 1783276945663852544
author Koleini, Navid
Nickel, Barbara E.
Wang, Jie
Roveimiab, Zeinab
Fandrich, Robert R.
Kirshenbaum, Lorrie A.
Cattini, Peter A.
Kardami, Elissavet
author_facet Koleini, Navid
Nickel, Barbara E.
Wang, Jie
Roveimiab, Zeinab
Fandrich, Robert R.
Kirshenbaum, Lorrie A.
Cattini, Peter A.
Kardami, Elissavet
author_sort Koleini, Navid
collection PubMed
description BACKGROUND: Cardiotoxic side effects impose limits to the use of anti-tumour chemotherapeutic drugs such as doxorubicin (Dox). There is a need for cardioprotective strategies to prevent the multiple deleterious effects of Dox. Here, we examined the ability of administered fibroblast growth factor-2 (FGF-2), a cardioprotective protein that is synthesized as high and low molecular weight (Hi-, Lo-FGF-2) isoforms, to prevent Dox-induced: oxidative stress; cell death; lysosome dysregulation; and inactivation of potent endogenous protective pathways, such as the anti-oxidant/detoxification nuclear factor erythroid-2-related factor (Nrf-2), heme oxygenase-1 (HO-1) axis. METHODS AND RESULTS: Brief pre-incubation of neonatal rat cardiomyocyte cultures with either Hi- or Lo-FGF-2 reduced the Dox-induced: oxidative stress; apoptotic/necrotic cell death; lysosomal dysregulation; decrease in active mammalian target of Rapamycin (mTOR). FGF-2 isoforms prevented the Dox-induced downregulation of Nrf-2, and promoted robust increases in the Nrf-2-downstream targets including the cardioprotective protein HO-1, and p62/SQSTM1, a multifunctional scaffold protein involved in autophagy. Chloroquine, an autophagic flux inhibitor, caused a further increase in p62/SQSTM1, indicating intact autophagic flux in the FGF-2-treated groups. A selective inhibitor for HO-1, Tin-Protoporphyrin, prevented the FGF-2 protection against cell death. The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1. CONCLUSIONS: In an acute setting Hi- or Lo-FGF-2 protect cardiomyocytes against multiple Dox-induced deleterious effects, by a mechanism dependent on preservation of mTOR activity, Nrf-2 levels, and the upregulation of HO-1. Preservation/activation of endogenous anti-oxidant/detoxification defences by FGF-2 is a desirable property in the setting of Dox-cardiotoxicity.
format Online
Article
Text
id pubmed-5675643
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56756432017-11-18 Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway Koleini, Navid Nickel, Barbara E. Wang, Jie Roveimiab, Zeinab Fandrich, Robert R. Kirshenbaum, Lorrie A. Cattini, Peter A. Kardami, Elissavet Oncotarget Research Paper BACKGROUND: Cardiotoxic side effects impose limits to the use of anti-tumour chemotherapeutic drugs such as doxorubicin (Dox). There is a need for cardioprotective strategies to prevent the multiple deleterious effects of Dox. Here, we examined the ability of administered fibroblast growth factor-2 (FGF-2), a cardioprotective protein that is synthesized as high and low molecular weight (Hi-, Lo-FGF-2) isoforms, to prevent Dox-induced: oxidative stress; cell death; lysosome dysregulation; and inactivation of potent endogenous protective pathways, such as the anti-oxidant/detoxification nuclear factor erythroid-2-related factor (Nrf-2), heme oxygenase-1 (HO-1) axis. METHODS AND RESULTS: Brief pre-incubation of neonatal rat cardiomyocyte cultures with either Hi- or Lo-FGF-2 reduced the Dox-induced: oxidative stress; apoptotic/necrotic cell death; lysosomal dysregulation; decrease in active mammalian target of Rapamycin (mTOR). FGF-2 isoforms prevented the Dox-induced downregulation of Nrf-2, and promoted robust increases in the Nrf-2-downstream targets including the cardioprotective protein HO-1, and p62/SQSTM1, a multifunctional scaffold protein involved in autophagy. Chloroquine, an autophagic flux inhibitor, caused a further increase in p62/SQSTM1, indicating intact autophagic flux in the FGF-2-treated groups. A selective inhibitor for HO-1, Tin-Protoporphyrin, prevented the FGF-2 protection against cell death. The mTOR inhibitor Rapamycin prevented FGF-2 protection, and blocked the FGF-2 effects on Nrf-2, HO-1 and p62/SQSTM1. CONCLUSIONS: In an acute setting Hi- or Lo-FGF-2 protect cardiomyocytes against multiple Dox-induced deleterious effects, by a mechanism dependent on preservation of mTOR activity, Nrf-2 levels, and the upregulation of HO-1. Preservation/activation of endogenous anti-oxidant/detoxification defences by FGF-2 is a desirable property in the setting of Dox-cardiotoxicity. Impact Journals LLC 2017-08-24 /pmc/articles/PMC5675643/ /pubmed/29152091 http://dx.doi.org/10.18632/oncotarget.20558 Text en Copyright: © 2017 Koleini et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Koleini, Navid
Nickel, Barbara E.
Wang, Jie
Roveimiab, Zeinab
Fandrich, Robert R.
Kirshenbaum, Lorrie A.
Cattini, Peter A.
Kardami, Elissavet
Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
title Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
title_full Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
title_fullStr Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
title_full_unstemmed Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
title_short Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway
title_sort fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mtor/nrf-2/ho-1 pathway
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675643/
https://www.ncbi.nlm.nih.gov/pubmed/29152091
http://dx.doi.org/10.18632/oncotarget.20558
work_keys_str_mv AT koleininavid fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT nickelbarbarae fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT wangjie fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT roveimiabzeinab fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT fandrichrobertr fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT kirshenbaumlorriea fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT cattinipetera fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway
AT kardamielissavet fibroblastgrowthfactor2mediatedprotectionofcardiomyocytesfromthetoxiceffectsofdoxorubicinrequiresthemtornrf2ho1pathway